Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.
Effect of Moderate Liver Impairment on the Pharmacokinetics of Saquinavir After Administration of Saquinavir/Ritonavir 1000/100mg BID in HIV Patients
Status: Enrolling
Updated:  2/28/2018
mi
from
Ottawa,
A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.
Effect of Moderate Liver Impairment on the Pharmacokinetics of Saquinavir After Administration of Saquinavir/Ritonavir 1000/100mg BID in HIV Patients
Status: Enrolling
Updated: 2/28/2018
mi
from
Ottawa,
Click here to add this to my saved trials
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462
Status: Enrolling
Updated:  3/1/2018
GSK Investigational Site
mi
from
Bakersfield, CA
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462
Status: Enrolling
Updated: 3/1/2018
GSK Investigational Site
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462
Status: Enrolling
Updated:  3/1/2018
GSK Investigational Site
mi
from
Fort Lauderdale, FL
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462
Status: Enrolling
Updated: 3/1/2018
GSK Investigational Site
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462
Status: Enrolling
Updated:  3/1/2018
GSK Investigational Site
mi
from
Orlando, FL
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462
Status: Enrolling
Updated: 3/1/2018
GSK Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462
Status: Enrolling
Updated:  3/1/2018
GSK Investigational Site
mi
from
Omaha, NE
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462
Status: Enrolling
Updated: 3/1/2018
GSK Investigational Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462
Status: Enrolling
Updated:  3/1/2018
GSK Investigational Site
mi
from
Camden, NJ
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462
Status: Enrolling
Updated: 3/1/2018
GSK Investigational Site
mi
from
Camden, NJ
Click here to add this to my saved trials
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462
Status: Enrolling
Updated:  3/1/2018
GSK Investigational Site
mi
from
Columbus, OH
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462
Status: Enrolling
Updated: 3/1/2018
GSK Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462
Status: Enrolling
Updated:  3/1/2018
GSK Investigational Site
mi
from
Philadelphia, PA
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462
Status: Enrolling
Updated: 3/1/2018
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462
Status: Enrolling
Updated:  3/1/2018
GSK Investigational Site
mi
from
Philadelphia, PA
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462
Status: Enrolling
Updated: 3/1/2018
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462
Status: Enrolling
Updated:  3/1/2018
GSK Investigational Site
mi
from
Dallas, TX
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462
Status: Enrolling
Updated: 3/1/2018
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462
Status: Enrolling
Updated:  3/1/2018
GSK Investigational Site
mi
from
Annandale, VA
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462
Status: Enrolling
Updated: 3/1/2018
GSK Investigational Site
mi
from
Annandale, VA
Click here to add this to my saved trials
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462
Status: Enrolling
Updated:  3/1/2018
GSK Investigational Site
mi
from
Seattle, WA
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462
Status: Enrolling
Updated: 3/1/2018
GSK Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462
Status: Enrolling
Updated:  3/1/2018
GSK Investigational Site
mi
from
Bobigny,
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462
Status: Enrolling
Updated: 3/1/2018
GSK Investigational Site
mi
from
Bobigny,
Click here to add this to my saved trials
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
CTN 0064: Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
Status: Enrolling
Updated:  3/1/2018
University Hospital, University of Alabama at Birmingham
mi
from
Birmingham, AL
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
CTN 0064: Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
Status: Enrolling
Updated: 3/1/2018
University Hospital, University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
CTN 0064: Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
Status: Enrolling
Updated:  3/1/2018
Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center
mi
from
Torrance, CA
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
CTN 0064: Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
Status: Enrolling
Updated: 3/1/2018
Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center
mi
from
Torrance, CA
Click here to add this to my saved trials
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
CTN 0064: Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
Status: Enrolling
Updated:  3/1/2018
Jackson Health System Adult HIV Outpatient Clinics / University of Miami
mi
from
Miami, FL
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
CTN 0064: Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
Status: Enrolling
Updated: 3/1/2018
Jackson Health System Adult HIV Outpatient Clinics / University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
CTN 0064: Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
Status: Enrolling
Updated:  3/1/2018
Grady Memorial Hospital / Ponce de Leon Center
mi
from
Atlanta, GA
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
CTN 0064: Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
Status: Enrolling
Updated: 3/1/2018
Grady Memorial Hospital / Ponce de Leon Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
CTN 0064: Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
Status: Enrolling
Updated:  3/1/2018
John H. Stroger, Jr. Hospital of Cook County
mi
from
Chicago, IL
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
CTN 0064: Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
Status: Enrolling
Updated: 3/1/2018
John H. Stroger, Jr. Hospital of Cook County
mi
from
Chicago, IL
Click here to add this to my saved trials
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
CTN 0064: Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
Status: Enrolling
Updated:  3/1/2018
Johns Hopkins Hospital / Moore Clinic
mi
from
Baltimore, MD
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
CTN 0064: Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
Status: Enrolling
Updated: 3/1/2018
Johns Hopkins Hospital / Moore Clinic
mi
from
Baltimore, MD
Click here to add this to my saved trials
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
CTN 0064: Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
Status: Enrolling
Updated:  3/1/2018
Boston University Medical Center
mi
from
Boston, MA
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
CTN 0064: Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
Status: Enrolling
Updated: 3/1/2018
Boston University Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
CTN 0064: Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
Status: Enrolling
Updated:  3/1/2018
Mount Sinai-St. Luke's Roosevelt Hospital Center
mi
from
New York, NY
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
CTN 0064: Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
Status: Enrolling
Updated: 3/1/2018
Mount Sinai-St. Luke's Roosevelt Hospital Center
mi
from
New York, NY
Click here to add this to my saved trials
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
CTN 0064: Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
Status: Enrolling
Updated:  3/1/2018
Hahnemann University Hospital
mi
from
Philadelphia, PA
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
CTN 0064: Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
Status: Enrolling
Updated: 3/1/2018
Hahnemann University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
CTN 0064: Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
Status: Enrolling
Updated:  3/1/2018
University of Pittsburgh Medical Center Presbyterian / Pittsburgh AIDS Center for Treatment
mi
from
Pittsburgh, PA
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
CTN 0064: Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
Status: Enrolling
Updated: 3/1/2018
University of Pittsburgh Medical Center Presbyterian / Pittsburgh AIDS Center for Treatment
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
CTN 0064: Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
Status: Enrolling
Updated:  3/1/2018
University of Texas Southwestern
mi
from
Dallas, TX
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
CTN 0064: Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
Status: Enrolling
Updated: 3/1/2018
University of Texas Southwestern
mi
from
Dallas, TX
Click here to add this to my saved trials
Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals
A Phase 1b Clinical Trial to Evaluate Mucosal Immune Responses to a DNA Plasmid Vaccine Prime Followed by an HIV-1 Adenoviral Vector Boost in Healthy Adenovirus Type 5 Seronegative HIV-1-uninfected Adults
Status: Enrolling
Updated:  3/5/2018
Seattle Vaccine and Prevention CRS
mi
from
Seattle, WA
Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals
A Phase 1b Clinical Trial to Evaluate Mucosal Immune Responses to a DNA Plasmid Vaccine Prime Followed by an HIV-1 Adenoviral Vector Boost in Healthy Adenovirus Type 5 Seronegative HIV-1-uninfected Adults
Status: Enrolling
Updated: 3/5/2018
Seattle Vaccine and Prevention CRS
mi
from
Seattle, WA
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Hobson City, AL
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Hobson City, AL
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Little Rock, AR
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Bakersfield, CA
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Bakersfield, CA
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Beverly Hills, CA
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Long Beach, CA
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Los Angeles, CA
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Oakland, CA
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Oakland, CA
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
San Diego, CA
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
San Francisco, CA
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Aurora, CO
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Aurora, CO
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Denver, CO
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Denver, CO
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Washington,
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Washington,
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Fort Lauderdale, FL
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Fort Pierce, FL
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Fort Pierce, FL
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Miami Beach, FL
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Miami Beach, FL
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Miami, FL
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Orlando, FL
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
West Palm Beach, FL
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Augusta, GA
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Augusta, GA
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Chicago, IL
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Maywood, IL
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Maywood, IL
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Iowa City, IA
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Baltimore, MD
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Boston, MA
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Springfield, MA
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Springfield, MA
Click here to add this to my saved trials